Q1 EPS Estimate for Phibro Animal Health Lifted by Analyst

Key Points

• Analysts at Zacks Research have raised their Q1 2026 earnings per share (EPS) estimate for Phibro Animal Health to $0.58, up from a previous forecast of $0.54, maintaining a "Strong-Buy" rating on the stock.
• Phibro Animal Health reported $0.57 EPS for Q2 2023, exceeding the consensus estimate of $0.52, with revenue reaching $378.70 million, higher than the expected $362.24 million.
• The company has recently announced a quarterly dividend of $0.12 per share, contributing to an annualized dividend of $0.48, which reflects a yield of 1.3%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Analysts at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for shares of Phibro Animal Health in a research report issued to clients and investors on Wednesday, October 8th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.58 for the quarter, up from their previous forecast of $0.54. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health's FY2026 earnings at $2.54 EPS and Q2 2027 earnings at $0.67 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

Several other research firms also recently issued reports on PAHC. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price on the stock in a report on Monday, June 16th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Phibro Animal Health in a research report on Saturday, September 27th. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Finally, Bank of America raised their target price on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Phibro Animal Health currently has a consensus rating of "Hold" and an average price target of $28.40.

Phibro Animal Health Stock Up 0.2%

Shares of NASDAQ PAHC opened at $37.17 on Friday. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $41.57. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25. The firm has a market cap of $1.51 billion, a PE ratio of 31.50, a price-to-earnings-growth ratio of 1.12 and a beta of 0.83. The company has a 50 day simple moving average of $35.45 and a 200 day simple moving average of $27.64.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd were issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend was Wednesday, September 3rd. Phibro Animal Health's payout ratio is currently 40.68%.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,022 shares of Phibro Animal Health stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $40.26, for a total transaction of $282,705.72. Following the transaction, the chief executive officer owned 31,338 shares of the company's stock, valued at $1,261,667.88. The trade was a 18.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 24,622 shares of company stock valued at $995,893 over the last three months. Corporate insiders own 50.13% of the company's stock.

Institutional Trading of Phibro Animal Health

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in Phibro Animal Health by 2.9% during the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company's stock worth $332,000 after purchasing an additional 363 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phibro Animal Health by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock worth $260,000 after buying an additional 546 shares during the last quarter. Prospera Financial Services Inc grew its holdings in shares of Phibro Animal Health by 3.6% in the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company's stock valued at $508,000 after acquiring an additional 690 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Phibro Animal Health by 7.6% in the second quarter. State of Alaska Department of Revenue now owns 12,129 shares of the company's stock valued at $309,000 after acquiring an additional 859 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Phibro Animal Health by 0.3% during the second quarter. Bank of New York Mellon Corp now owns 268,877 shares of the company's stock valued at $6,867,000 after acquiring an additional 906 shares during the last quarter. Institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.